ライフサイエンスコーパス: contrast agent

1 applied field strength and administration of contrast agent.

2 anges were not significantly associated with contrast agent.

3 ier, but not with gadofosveset, a blood-pool contrast agent.

4 imited by the cytotoxic levels of the Mn(2+) contrast agent.

5 subharmonic imaging during infusion of a US contrast agent.

6 anelle motility inside somas as an intrinsic contrast agent.

7 as well as to the local administration of a contrast agent.

8 K-1, in addition to serving as an ultrasound contrast agent.

9 tially be favorable for use as a clinical CT contrast agent.

10 technique by employing a stimuli-responsive contrast agent.

11 ponses, if acquired with a molecular imaging contrast agent.

12 ol has gained considerable interest as an MR contrast agent.

13 ength and administration of gadolinium-based contrast agent.

14 e level without the need for any staining or contrast agent.

15 ensitivity of a hyperpolarized xenon-129 MRI contrast agent.

16 h gold nanoparticles (AuNP) and an iodinated contrast agent.

17 repeated administration of gadolinium-based contrast agents.

18 ers are widely used clinically as ultrasound contrast agents.

19 ostic quality was equivalent between the two contrast agents.

20 ravenous injection of hepatobiliary-specific contrast agents.

21 the most successful near-infrared (NIR) USF contrast agents.

22 their use for in vivo delivery of drugs and contrast agents.

23 gth sensitivity without the use of exogenous contrast agents.

24 ar 'blueprint'; this could be supplied using contrast agents.

25 gical processes with systemically introduced contrast agents.

26 r the design of biochemically responsive MRI contrast agents.

27 ss of USF imaging highly relies on excellent contrast agents.

28 linked to exposure to gadolinium-containing contrast agents.

29 the development of activatable molecular MR contrast agents.

30 developing fluoride-responsive complexes and contrast agents.

31 blood plasma is comparable to commercial Gd contrast agents.

32 ts the translational potential of MPIO-based contrast agents.

33 duce cavitation of lipid-shelled microbubble contrast agents.

34 linical and research use of gadolinium-based contrast agents.

35 nitude higher than those of gadolinium-based contrast agents.

36 able potential for employment of specialized contrast agents.

37 al clinical translation of molecular imaging contrast agents.

38 ions in a phantom containing mixtures of the contrast agents.

39 hout exposure to iodine- or gadolinium-based contrast agents.

40 al outcome after MI without gadolinium-based contrast agents.

41 ially noise-limited detection of fluorescent contrast agents.

42 oints after injections of AuNP and iodinated contrast agents.

43 rucial to the design of high-performance MRI contrast agents.

44 iled Gradient Echo method at 9.4 T using two contrast agents: a clinically approved Gd chelate, Multi

45 molecular imaging by MRI requires the use of contrast agents able to recognize specifically a peculia

46 Results In patients with rectal contrast agent administration (n = 151), AUCs were 0.90-

47 (AUC, 0.86-0.99) in the group without rectal contrast agent administration (n = 31).

48 The quality of the colorectal contrast agent administration was recorded.

49 acy remained high in patients without rectal contrast agent administration.

50 g T1-weighted, T2-weighted, before and after contrast agent administrtion T2 fluid attenuation invers

51 y found to act as both a H2O2-responsive MRI contrast agent and a mimic of superoxide dismutase (SOD)

52 gahertz pulsed ultrasound in the presence of contrast agent and assessed the efficiency of fluorescen

53 and HIFU are limited by the half-life of the contrast agent and challenges in accurate control of lar

54 le of a Cu-based PARACEST magnetic resonance contrast agent and demonstrate the potential to expand t

55 ent production of payloads of hyperpolarized contrast agent and in situ quality assurance of the prod

56 ed noninvasively using an albumin-binding MR contrast agent and may be used as surrogate markers for

57 shell) nanoparticles (GTNPs@PANI) as an OCT contrast agent and pH-responsive nanoprobe for 3D imagin

58 e rat brain 1 and 20 weeks after dosing with contrast agent and to determine if there are any histopa

59 The contrast agents and calcium phosphate were imaged in pha

60 obtained by combining a variety of different contrast agents and fixative treatments that provides ge

61 uable tool for in vitro fertilization, where contrast agents and fluorophores may impact the viabilit

62 nderstanding of the biodistribution of these contrast agents and their safety.

63 laxivity comparable to that of Gd(III)-based contrast agents and undergo spontaneous cytosolic locali

64 Ten pharmaceuticals, an X-ray contrast agent, and an artificial sweetener were studied

65 At one-tenth the current clinical dose of contrast agent, and following a single imaging session,

66 cially deeper pockets) were treated with the contrast agent, and the probing depths were measured wit

67 n diverse fields such organic magnetism, MRI contrast agents, and spintronics.

68 typically low concentrations of fluorescent contrast agents, and tissue motion.

69 al ions; as nonlinear optical materials, MRI contrasting agents, and sensitizers for photodynamic the

70 Although some linear contrast agents appear to cause greater MRI signal chang

71 Near-infrared (NIR) fluorescent contrast agents are emerging in optical imaging as sensi

72 f photoacoustic imaging, novel photoacoustic contrast agents are highly desired for molecular imaging

73 Additionally, microbubble contrast agents are improving the sensitivity and specif

74 However, most gadolinium (Gd)-chelator MR contrast agents are limited by their relatively low rela

75 Most MRI contrast agents are polar and membrane impermeant, makin

76 Conclusion Iron-based contrast agents are promising as alternatives for contra

77 Although iodinated contrast agents are relatively safe and widely used, adv

78 As no contrast agents are required, this label-free imaging ap

79 These contrast agents are used for ultrafast molecular imaging

80 n microscopy, where individual microbubbles (contrast agents) are detected and tracked within the vas

81 cal proof of concept for use of this imaging contrast agent as administered before surgery to dogs wi

82 ing the relative merits of the vast range of contrast agents available, from small-molecule dyes to g

83 e ocular vasculature without using exogenous contrast agents, avoiding associated side effects.

84 eptor binding, in contrast to the use of MRI contrast agents based on agonists that tend to be intern

85 tion, 28 (34.1%) received a gadolinium-based contrast agent before and had no reaction.

86 context, retention is a measure of molecular contrast agent binding.

87 s, metabolic precursors and nuclear medicine contrast agents) by single cells without perturbing endo

88 antum dot (B-GQD) as a metal-free multimodal contrast agent (CA) for safe magnetic resonance imaging

89 arge-scale synthesis of a cationic iodinated contrast agent (CA4+) is described for imaging articular

90 dual-mode, dual-Gadolinium (DM-Dual-Gd-ICG) contrast agent can be used to visualize ovarian tumors i

91 We show that this new contrast agent can generate up to 30 times stronger phot

92 ssues labeled in vivo with gold nanoparticle contrast agents can be detected using SFHI.

93 Nonionic iodinated contrast agents can be divided into monomeric, low-osmol

94 classification of different tissue types and contrast agents can be extremely challenging.

95 +)-based T1 magnetic resonance imaging (MRI) contrast agents (CAs) are suboptimal or unsuitable, espe

96 The relaxivity of the contrast agent changes by a factor of 6.7.

97 cm at 1064 nm excitation is achieved with a contrast-agent concentration as low as 40 microg mL(-1)

98 n the tissues allowing quantification of the contrast agents' concentrations, which matched their exp

99 ation with Gd, this PTPmu-targeted molecular contrast agent containing a single Gd ion showed signifi

100 olecular-weight Gd(III) -based PSMA-targeted contrast agents containing one to three Gd(III) chelates

101 inium-based magnetic resonance imaging (MRI) contrast agent, CREKA-Tris(Gd-DOTA)3 (Gd-DOTA (4,7,10-tr

102 bolus administration of iodinated non ionic contrast agent; CT images demonstrated the presence of a

103 protein crystallization, as drug and medical contrast agent delivery vehicles, and as biosensors and

104 ing, and in vivo application of pH-sensitive contrast agents designed specifically for Cerenkov imagi

105 s, in contrast, are ultrastable, fluorescent contrast agents detectable even at the single nanopartic

106 not completely sGAG specific and requires a contrast agent, dGEMRIC is a validated and robust method

107 All of the contrast agents distributed in foci around the cortex an

108 ith greater sensitivity, and may allow lower contrast agent doses to be used.

109 ble to identify tumor-induced alterations in contrast agent drainage into the popliteal LN, while low

110 The application of iodinated contrast agents during diagnostic x-ray procedures, such

111 etric cardiac and respiratory motion phases, contrast-agent dynamics, and blood flow velocity fields.

112 the commercially available echocardiographic contrast agents (ECA) Definity and Optison after spontan

113 A contrast agent enema may be used to confirm or exclude l

114 ull-field digital (FFD) mammography, dynamic contrast agent-enhanced (DCE) magnetic resonance (MR) im

115 ation, to study its correlation with dynamic contrast agent-enhanced (DCE) magnetic resonance (MR) im

116 20-89 years]) were obtained before and after contrast agent-enhanced cardiac MR imaging.

117 Materials and Methods Contrast agent-enhanced CT findings in a cohort of 256 p

118 routine nonenhanced and portal venous phase contrast agent-enhanced liver CT imaging with thick-sect

119 Radiation dose-matched delayed contrast agent-enhanced spiral and axial abdominal EID a

120 , color Doppler US, strain elastography, and contrast agent-enhanced US in the assessment of intrates

121 ever received injections of gadolinium-based contrast agent) examined with a standard T1-weighted two

122 In a separate cohort of rats, an MRI contrast agent, Feraheme(R) (USPIO), was administered 2d

123 tify the local concentration of multiple MRI contrast agents following simultaneous administration.

124 The dose of the contrast agent for effective molecular MRI is only sligh

125 detect cancer cells and a photoacoustic (PA) contrast agent for imaging-guided cancer therapy.

126 P=0.25% for hydroxyethyl propionate, a known contrast agent for magnetic resonance angiography.

127 oxygen encapsulated bubbles as an ultrasound contrast agent for methylation reversal is expected to h

128 SiNc appears to be a promising family of contrast agent for optoacoustic imaging.

129 nanoparticles (TSPNs) are investigated as a contrast agent for photoacoustic (PA) imaging in the sec

130 operoxidase (MPO), might be a more sensitive contrast agent for the detection of multiple sclerosis (

131 yperpolarized (hp) (83)Kr is a promising MRI contrast agent for the diagnosis of pulmonary diseases a

132 with those of a commercial gadolinium-based contrast agent for their applicability in dynamic contra

133 gnificant application of PHIP is to generate contrast agents for biomedical imaging.

134 lasmonic nanoparticles are explored as image contrast agents for both superlocalization and super-res

135 PET/MR scanners, the utility and need for MR contrast agents for combined scans is questioned.

136 per complexes for potential use as (19)F MRI contrast agents for detecting cellular hypoxia.

137 ng (SERRS) nanoparticles make them promising contrast agents for in vivo cancer imaging.

138 other Gd-chelates, making them the promising contrast agents for magnetic resonance imaging (MRI).

139 e been used for treating iron deficiency, as contrast agents for magnetic resonance imaging and as dr

140 itals and research centers that use Gd-based contrast agents for magnetic resonance imaging.

141 by nanoparticle "strings" are useful both as contrast agents for photoacoustic imaging and as light-a

142 We met this challenge by developing novel contrast agents for retinopathy, which we used with magn

143 hy, its interpretation, and intravasation of contrast agents for safer procedure and to minimize the

144 e Au nanocups exhibit superior efficiency as contrast agents for spectral-domain optical coherence to

145 hese DHCA functionalized IONPs are promising contrast agents for stem cell tracking by T2-weighted MR

146 that remain for polymer coated IONPs as MRI contrast agents for stem cell tracking.

147 ntribute to the development of new DNA-based contrast agents for superresolution imaging.

148 igational optical imaging devices as well as contrast agents for surgical applications.

149 t property of AuNPs is that they also act as contrast agents for X-ray microtomography and electron m

150 citation, denoted as beta, serves as a vital contrasting agent for imaging local environment.

151 Contrast agent free ultrasound imaging, computed tomogra

152 Compared with reference Gd2O3 and contrast agent Gadodiamide, the features in the RIXS spe

153 T1 mapping using an albumin-binding contrast agent (gadofosveset) could quantify the changes

154 resonance imaging using the albumin-binding contrast agent, gadofosveset, is a surrogate marker of r

155 the applicability of the albumin-binding MR contrast agent, gadofosveset, to noninvasively monitor f

156 epeated administration of the liver-specific contrast agent gadoxetic acid.

157 (MR) images with increasing gadolinium-based contrast agent (GBCA) doses in patients who received 35

158 ities following intravenous gadolinium-based contrast agent (GBCA) exposure might be related to blood

159 jections of the macrocyclic gadolinium-based contrast agent (GBCA) gadoterate meglumine on the signal

160 pediatric brain to a linear gadolinium-based contrast agent (GBCA) is associated with an increase in

161 epatic function who undergo gadolinium-based contrast agent (GBCA)-enhanced magnetic resonance (MR) i

162 ltiple intravenous doses of gadolinium-based contrast agent (GBCA).

163 ing after administration of gadolinium-based contrast agents (GBCA) for magnetic resonance imaging (M

164 tween the administration of gadolinium-based contrast agents (GBCAs) and gadolinium retention in bone

165 contrast-enhanced MRI, and gadolinium-based contrast agents (GBCAs) are the mainstream MRI contrast

166 who had not received linear gadolinium-based contrast agents (GBCAs) but had received many injections

167 iple administrations of the gadolinium-based contrast agents (GBCAs) gadodiamide and gadoteridol and

168 stration of the macrocyclic gadolinium-based contrast agents (GBCAs) gadoteridol and gadoterate meglu

169 l injections of macrocyclic gadolinium-based contrast agents (GBCAs) on the signal intensity (SI) of

170 Gadolinium-based contrast agents (GBCAs), once believed to be safe for pa

171 nt of the administration of gadolinium-based contrast agents (GBCAs).

172 c events between classes of gadolinium-based contrast agents (GBCAs).

173 th prior exposure to linear gadolinium-based contrast agents (GBCAs).

174 t Ktrans describing extravasation of the MRI contrast agent Gd-DTPA was significantly increased in bo

175 f a previously reported Zn(II)-sensitive MRI contrast agent, GdDOTA-diBPEN, new structural targets we

176 In each case, the contrast agents gives rise to robust T1-weighted MRI enh

177 application of more than a single molecular contrast agent has been limited by MRI's ability to only

178 st associated with the structurally modified contrast agents has been performed.

179 AM-alkyl complexes as potential PARACEST MRI contrast agents has been synthesized with the aim to dec

180 lar magnetic resonance with gadolinium-based contrast agents has established as gold standard for tis

181 The scope of available MRI contrast agents has expanded over the years with the eme

182 netic iron oxide nanoparticles (SPIONs) as a contrast agent have been widely used in magnetic resonan

183 While a number of OCT contrast agents have been previously studied, demonstrat

184 diagnostic magnetic resonance imaging (MRI) contrast agents have been reported, the metallofullerene

185 Injectable Magnetic Resonance Imaging (MRI) contrast agents have been widely used to provide critica

186 These NIR contrast agents have potential for clinical translation

187 haracteristics of the existing photoacoustic contrast agents, highlighting key applications and prese

188 pically used low molecular weight gadolinium contrast agents, however larger gadolinium-loaded nanopa

189 norganic materials, and thus can be used as 'contrast agents' if biologically absent elements are enc

190 pectrum potentially allows simultaneous dual contrast agent imaging, however, this has not yet been d

191 the concentration of a gadolinium-containing contrast agent in a region of interest, thereby allowing

192 t in gold nanoparticles enables their use as contrast agents in a variety of applications for compoun

193 oxide nanoparticles (IONPs) could be used as contrast agents in magnetic resonance imaging (MRI) that

194 irst implementation of gadolinium(III)-based contrast agents in magnetic resonance imaging in the 198

195 es), which can enable new uses of ultrasound contrast agents in molecular imaging and drug delivery,

196 ations have shown extraordinary potential as contrast agents in various bioimaging modalities, near-I

197 ow, where background signals from endogenous contrast agents, including blood and lipid, are at the l

198 s potential characteristics for targeted MRI contrast agents, including high relaxivity, unappreciabl

199 an 9 minutes examination time, works without contrast agent injection, and offers a diagnostic accura

200 en hypothesized as an alternative ultrasound contrast agent instead of gas-core agents.

201 gadoteridol, an exogenous magnetic resonance contrast agent intravenously injected.

202 (n=73) after application of 70 to 120 mL of contrast agent, Iomeprol 300.

203 ntravenous administration of a pH-responsive contrast agent (iopamidol).

204 ase-3-sensitive nanoaggregation MRI (C-SNAM) contrast agent is reported.

205 ned with superparamagnetic iron-oxide (SPIO) contrast agents is an effective cell-tracking method.

206 The application of targeted MRI contrast agents is particularly well-suited to this task

207 The purely intravascular nature of US contrast agents is valuable as the rapid washout of nonh

208 t and ovarian lesions using a clinical-grade contrast agent (kinase insert domain receptor [KDR] -tar

209 The contrast agent kinetic characteristics of T1-weighted DC

210 Semiquantitative parameters of contrast agent kinetics were calculated from the relativ

211 nning was done, which allowed measurement of contrast agent kinetics with high temporal resolution.

212 olumetric visualization of moving organs and contrast agent kinetics, molecular imaging using targete

213 In addition, the USPIO contrast agent labeled macrophages were shown to be pres

214 tom algorithms to spectrally identify unique contrast agents: large gold nanorods (LGNRs).

215 Contrast agent leak was highly specific (96%-98%), but i

216 tory had excellent sensitivity, while rectal contrast agent leak was specific but insensitive.

217 Additional signs evaluated were rectal contrast agent leak, collections of extruded fecal mater

218 rtcoming, we demonstrate the use of a living contrast agent, magneto-endosymbionts (MEs) derived from

219 ganese-based magnetic resonance (MR) imaging contrast agent manganese-N-picolyl-N,N',N'-trans-1,2-cyc

220 Here, we developed contrast agent mass spectrometry imaging (CA-MSI) that u

221 ombined with systemic infusion of ultrasound contrast agent microbubbles (MB) causes localized blood-

222 focused ultrasound (FUS) in conjunction with contrast agent microbubbles may be used to non-invasivel

223 ssible with nanoparticle presentation of the contrast agent molecules.

224 herent contrast detectable by OCT, exogenous contrast agents must be employed for imaging specific ce

225 These contrast agents of 6-8 mum in diameter can circulate thr

226 ngths (1, 1.5, 3, and 7 T) and the effect of contrast agent on DNA double-strand-break (DSB) formatio

227 To assess the effect of this hepatobiliary contrast agent on T2-weighted TSE images and DW images T

228 scanned phantoms containing either an iodine contrast agent or gold nanoparticles.

229 two decades, either as effective bio-imaging contrast agents or as carriers of biomolecules such as d

230 s, nucleic acids, magnetic resonance imaging contrast agents or catalysts.

231 ith a folate receptor targeted near-infrared contrast agent (OTL38) can improve malignant pulmonary n

232 f folate receptor (FR)-targeted phase-change contrast agents (PCCAs) in MDA-MB-231 and MCF-7 breast c

233 bicin (Dox) were co-loaded with a nanobubble contrast agent (perfluoropentane, PFP) using a one-step

234 The typical method for creating targeted contrast agents requires covalent conjugation of separat

235 l lanthanide complexes relavant to PARASHIFT contrast agents reveals unexpected trends in the magneti

236 some of these problems by combining MRI with contrast agents sensitive to neural signaling.

237 iary phase imaging, only gadoxetate disodium contrast agent showed significant independent associatio

238 Gadoxetate disodium contrast agent showed the strongest association with inc

239 on (GE Healthcare, Oslo, Norway) microbubble contrast agent solution (perflutren protein-type A micro

240 ed by X-ray computed tomography imaging of a contrast agent solution infiltrating the mesh.

241 tered a folate receptor-targeted fluorescent contrast agent specific for primary lung adenocarcinomas

242 ears with the emergence of molecular imaging contrast agents specifically targeted to biological mark

243 ties of the cells and requires no additional contrast agent, stain or label to image the cell structu

244 globin, fat, melanin, and water or exogenous contrast agents such as dyes and nanoparticles.

245 ilizes high frequency ultrasound without any contrast agents such as microbubbles, bringing a single-

246 Validation of imaging contrast agents, such as fluorescently labeled imaging a

247 utilizes a magnetic resonance imaging (MRI) contrast agent targeted to disease sites, as a label, to

248 ors develop a targeted peptide gadofullerene contrast agent that can sensitively distinguish between

249 often requires the addition of an exogenous contrast agent that may have limited tissue access.

250 a new biochemically responsive Mn-based MRI contrast agent that provides a 9-fold change in relaxivi

251 lso a large number of novel, cancer-specific contrast agents that are in early stage clinical trials

252 OCT have been limited by a lack of exogenous contrast agents that can be distinguished from tissue.

253 There is a need in surgical oncology for contrast agents that can enable real-time intraoperative

254 storage and multistage release of drugs and contrast agents that can facilitate the diagnosis and tr

255 and in vivo testing of two multimeric NIR-MR contrast agents that contain three Gd(III) chelates and

256 he tissue structure but lacks specificity to contrast agents that could be used for in vivo molecular

257 evelopment and clinical use of molecular MRI contrast agents that could provide vital diagnostic info

258 Contrast agents that go beyond qualitative visualization

259 proach provides a platform for molecular MRI contrast agents that is potentially more suitable for tr

260 We have created contrast agents that selectively quench photons emitted

261 in perfusion can be augmented by microbubble contrast agents that undergo ultrasound-mediated cavitat

262 Microbubble contrast agents that undergo ultrasound-mediated cavitat

263 Aided by tumor-targeted contrast agents, the system detected tumors in subcutane

264 exploit the potential of these materials as contrast agents, there is still a need for a greater und

265 For magnetic resonance contrast agents, this rotation results in diminished rel

266 Further DESI-MS imaging of the flux of the contrast agent through mouse kidneys was performed indic

267 ed to a corresponding time-varying iodinated contrast agent to create the contrast material-enhanced

268 R-based reconstruction techniques will allow contrast agents to be detected with greater sensitivity,

269 to standardize surgical navigation tools and contrast agents to facilitate swift regulatory approval.

270 of difficulties in delivering electron-dense contrast agents to specific subcellular targets within i

271 ime that microbeads (microBs) can be used as contrast agents to target cellular biomarkers in lymphat

272 the MEs are robust and effective biological contrast agents to track iCMs in an in vivo murine model

273 Addition of contrast agents (trypan blue or brilliant blue R) improv

274 m(2) [59-171 Grayxcm(2)]; P=0.06), and lower contrast agent use (200 mL [150-310 mL] versus 250 mL [2

275 clinical studies on the safety of gadolinium contrast agent use in pregnancy.

276 nd sex, whether premedication was given, the contrast agent used, the volume injected, the patient's

277 ntrast agents (GBCAs) are the mainstream MRI contrast agents used in the clinic.

278 shown promise for visualization of molecular contrast agents used to study disease in vivo.

279 yperpolarizer producing (13)C hyperpolarized contrast agents using parahydrogen induced polarization

280 Contrast agent was administrated intravenously.

281 Extravasation of the contrast agent was defined as anastomotic leakage.

282 rast swallow with the use of a water-soluble contrast agent was performed on the 5(th) postoperative

283 Low-dose CT without contrast agent was used for anatomic localization and at

284 A novel class of near-infrared fluorescent contrast agents was developed.

285 n which the presence of fibrosis or paraCEST contrast agents was directly encoded into the steady-sta

286 ty of liposomal Gadolinium (Gd) nanoparticle contrast agents was evaluated in a pregnant mouse model.

287 rs to serve as tumour-selective fluorescence contrast agents, we demonstrate the capability of a cons

288 in both the presence and the absence of the contrast agent were tested by using an independent sampl

289 tional CT section, absorption values of both contrast agents were similar at approximately 110 HU.

290 eted perfluorocarbon nanoemulsions (PFCs) as contrast agent, which is cross-linked to fibrin by activ

291 These native-tissue contrast agents will arm surgeons with a powerful and ve

292 -targeted, molecular magnetic resonance (MR) contrast agent with a single gadolinium (Gd) chelate usi

293 enhance with gadobutrol, a gadolinium-based contrast agent with high propensity to extravasate acros

294 To address a perceived need for a Gd-free contrast agent with pharmacokinetic and imaging properti

295 y enable production of (13) C hyperpolarized contrast agents with %P13C of 20-50 % in seconds using t

296 By dynamically modulating signals from the contrast agents with an external near-infrared optical s

297 The performance of three gadolinium contrast agents with different sizes and properties was

298 h was started 5 seconds after injection of a contrast agent, with a scan at 200 mAs, followed after 4

299 vivo detection of the cucurbit[6]uril (CB6) contrast agent within the vasculature of a living rat.

300 monstrate that, even in the absence of X-ray contrast agents, X-ray computed microtomography (microCT